Elsalys Biotech : New studies confirm anti-CD160 potential

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
52
Elsalys Biotech : New studies confirm anti-CD160 potential in ophthalmology

New studies confirm anti-CD160 antibodies are potential therapeutics for ophthalmic diseases

  • Efficacy and safety are consistently demonstrated in several in vivo preclinical models
  • Anti-CD160 is a potent inhibitor of ocular vascularization, alone and in combination with anti-VEGF treatment
  • Anti-CD160 could be a good alternative for poor responders to anti-VEGF treatments

Lyon, FRANCE, 2 July 2018, ELSALYS BIOTECH, a new player in immuno-oncology, announces the publication of two studies validating the potential of its first-in-class anti-CD160 antibodies for the treatment of neovascular diseases of the eye. The first study reveals that in patients, CD160 endothelial expression in retinal vessels is higher and correlates with a wide range of ocular neovascular diseases, while the second reports the safety of the antibody and demonstrates, in relevant animal models, its therapeutic benefit alone and in combination with anti-VEGF agents, the current standards of care for retinal vascular pathologies. Published in Investigative Ophthalmology & Visual Science , the results of these two studies confirm ELSALYS BIOTECH's preclinical data in ophthalmology: CD160 antibodies could be used (i) for its additive or synergistic effect with the current standard of care, or (ii) as alternative therapies in patients with anti-VEGF-resistant or refractory neovascular diseases.

Neoangiogenesis is a process by which new blood vessels form abnormally. It is responsible for a number of corneal/retinal diseases such as ischemic retinopathies (IRs) or choroidal retinopathies, which include exudative or ''wet'' age-related macular degeneration (wAMD). These diseases are the primary cause of moderate to severe vision loss in developed countries and are essentially treated with agents that target the VEGF (a growth factor that stimulates blood vessel). These standards of care are effective and safe, but present however variable responses between patients and are often associated with the development of treatment-resistance. Approximately 30% of wAMD patients treated with anti-VEGF therapies are considered treatment-resistant or having refractory neovascular AMD [1] . For these patients as well as for those that respond incompletely to anti-VEGF therapy, there is a pressing need to develop VEGF-independent complementary and synergistic therapies that inhibit pathological neovascularization while having little or no effect on normal mature tissue vasculature.

CD160: a first-in-class target for the treatment of retinal neovascular diseases

CD160 was already known to be a marker of activated endothelial cells that surround newly formed blood vessels, and as such is considered a potential target for the treatment of diseases associated with neoangiogenesis [2] . Henry et al. have now studied CD160 expression in the human eye and find that it is actually expressed mainly in endothelial cells and across some other cell types. Importantly, they reveal that its levels of expression are significantly higher in the retina of patients suffering from a range of ocular neovascular diseases, strongly supporting that CD160 could well represent an interesting target for novel anti-angiogenic therapies for these patients .

Anti-CD160 is a potent inhibitor of ocular vascularization, both alone and in combination with anti-VEGF treatment

Previous studies had shown that the engagement of CD160 by an activating antibody induces cell death of endothelial cells that surround newly formed blood vessels, thereby blocking their formation, both in vitro and in vivo 2, [3] . In the second publication, Menguy et al. assessed the efficacy of this antibody as a monotherapy or as a combination therapy with bevacizumab, a monoclonal antibody that targets the VEGF . They show that administration of an anti-CD160 has an antiangiogenic effect in vivo in a relevant model of corneal neovascularization. This effect is equivalent to that seen with bevacizumab (Figure 1A) or with aflibercept, a drug that also inhibits the VEGF pathway.

Figure 1. Efficacy of anti-CD160 treatment compares to (A) and additively combines with an anti-VEGF treatment (B). CL1-R2: anti-CD160 antibody .

Strikingly, the antiangiogenic effect of the combination treatment (anti-CD160 and bevacizumab) was significantly higher than either antibody alone (Figure 1B), strongly arguing that the anti-CD160 (i) may act independently of the VEGF pathway and (ii) could be a good alternative for patients that poorly respond to an anti-VEGF treatment. Interestingly, the additive effect observed upon treatment with CL1-R2 in combination with bevacizumab in the CNV rabbit model suggests that both CD160 and VEGF pathways contribute to the efficacy observed, and that the two mAbs probably act via different pathways. This could result in new therapeutic opportunities for co-targeted or combination therapies alongside anti-VEGFs.

Anti-CD160 is safe and efficacious in primate

Efficacy of anti CD160 was then confirmed on choroidal neovascularisation in the most relevant primate model. Beyond the efficacy data, the CD160 antibody causes no treatment-related adverse effects in the most relevant animal model of wAMD, (a primate model of laser-induced choroidal neovascularisation) , confirming the safety of targeting CD160 when treating retinal neovascular diseases.

 "These results demonstrate that a combination with anti-CD160 provides a tangible alternative to patients suffering from neovascular diseases of the eye.", explains Christine Guillen, CEO and Co-founder, ELSALYS BIOTECH .   " With these positive results in hand, we are excited to move forward towards a first clinical trial with CD160 antibody in ophthalmology and confident in the continuation of the program with our partner THEA laboratories that could exercise the option taken in February 2018 on ELB011 before end of 2018 [4] ."

***

About ELB011 - anti-CD160 antibody in ophthalmology

ELB011 is a first-in-class anti-angiogenic antibody with an innovative mechanism of action that inhibits anarchical neovascularization resulting in the normalization of vascularization in retinal vascular pathologies. The innovative mechanism of action of ELB011 makes it possible to consider its development in monotherapy or in combination with anti-VEGF agents, the current standard of care for these pathologies, whose efficacy can diminish with time of treatment.

In February 2018, ELSALYS BIOTECH has signed a license option agreement with THEA for the development of its ELB011 program in ophthalmology. The option concerns the clinical development (expected from 2020) and the commercialization of ELB011 in the treatment of wAMD and other retinal vascular pathologies.

About ELSALYS BIOTECH

ELSALYS BIOTECH is a clinical stage immuno-oncology company targeting tumors and their immune and/or vascular microenvironment.

To convert these novel targets into drug candidates, the Company is currently conducting 5 proprietary development programs including LEUKOTAC ® (inolimomab), an immunotherapy antibody that has recently demonstrated its clinical superiority in Phase 3 and that is closed to market approval in an orphan "post-cancer" disease with very poor prognosis: steroid-resistant acute Graft-versus-Host Disease.

Founded in 2013, ELSALYS BIOTECH is located in the heart of the European cluster LYON BIOPOLE. Its shareholders are TRANSGENE, SOFIMAC INNOVATION, IM EUROPE, a subsidiary of INSTITUT MERIEUX, and CREDIT AGRICOLE CREATION.

 

Stay in touch with ElsaLys Biotech and receive directly our press releases by filling our contact form on www.elsalysbiotech.com

And follow us on Twitter: @ElsalysBiotech

Contacts

  ELSALYS BIOTECH Dr. Christine GUILLEN CEO and Co-founder +33 (0)4 37 28 73 00 guillen@elsalysbiotech.com       PRESSE ATCG PARTNERS Marie PUVIEUX (France) +33 (0)6 10 54 36 72 Céline VOISIN (UK/US) +33 (0)6 62 12 53 39 presse@atcg-partners.com  

[1] Yang S et al. Drug Des Devel Ther. 2016

[2] Chabot et al. J Exp Med. 2011

[3] Fons et al., Blood 2006

[4] See press release of February 22, 2018, on the agreement with THEA Laboratoires

Attachment

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Lecanemab Shines in 5-Year Alzheimer's Study at CTAD

Updated Category News Views 163

Latest Lecanemab Results Turn Heads at CTAD 2026 The whispers buzzing out of the CTAD 2026 conference are about something promising for those in the trenches of Alzheimer's research: lecanemab. Yep, it's a name that's been bandied about before, and this time it's the long-term data doing the talking. The five-year results from Eisai and Biogen's lecanemab study are...

Continue Reading
Choate's Expands to New Mid-South Markets

Updated Category News Views 171

Family Traditions Drive Choate's Growth Back in the day, you might've thought the family-run businesses were a dying breed, right? Not in the case of Choate's Air Conditioning, Heating, Plumbing & Electrical. These folks aren't just holding the fort; they're storming new territories across the Mid-South like they've got something to prove—or maybe just something to...

Continue Reading
Saint Luis Rey Launches Exclusive Palatinos Vitola

Updated Category News Views 130

New Beginnings for the Saint Luis Rey Brand You think you've seen it all in the cigar world, but then comes a debut like this that lights a fire under the lush tradition of Cuba. Enter Saint Luis Rey's new Palatinos vitola, a blend wrapped in the mystique of exclusivity for La Casa del Habano and Habanos Specialists. Whether you're a seasoned connoisseur or just dipping...

Continue Reading
Daymond John's Four-Center Bet on Longevity Game

Updated Category News Views 221

A Shark's Dive into Longevity Here you go—Daymond John, the face of FUBU and a household name from Shark Tank, is not just talking about living longer; he's putting his wallet where his words are. John is jumping into the longevity game with both feet, joining Ultimate Longevity Center's (ULC) latest venture. We're talking about four new centers across California,...

Continue Reading
NVCA Refreshes Key Venture Legal Documents for 2026

Updated Category News Views 115

Keeping Pace with Evolving Venture Norms Change never lets up in the fast-paced world of venture capital, does it? Just when you think you've got the rules figured out, the game shifts. This time, it's the National Venture Capital Association (NVCA) shaking things up. They've given a facelift to seven of their model legal documents, a move that reshapes the legal...

Continue Reading
Nauticus Robotics Dive into Defense & UAE Moves

Updated Category News Views 211

Charting New Waters: Defense and UAE Focus Looking at Nauticus Robotics lately, it feels like they're finally getting the hang of balancing their defense play and UAE expansions. This quarter they're coming out swinging, dropping some fine numbers mixed with a slew of strategic moves that got me thinking twice about their place in the subsea robotics world. Financial...

Continue Reading
Sinch Appoints Jonas Dahlberg as New CEO: A Strategic Move

Updated Category News Views 74

A Change at the Helm: Dahlberg Takes Charge Here we go, folks—Sinch, that global powerhouse in customer communications, just got itself a new captain. Jonas Dahlberg is now officially the CEO, after warming the acting CEO seat since June. This ain't your ordinary office shuffle. It's a calculated chess move in the high-stakes tech world. Dahlberg's Path to the Top This...

Continue Reading
equipifi's BNPL Shop: New Ammo for Credit Unions

Updated Category News Views 189

equipifi's 'Shop': The Big Play in Banking Look, here’s the deal—equipifi just lobbed a new grenade into the finance battlefield, arming credit unions and community banks with 'Shop', their own Buy Now, Pay Later (BNPL) platform. The goal? To put them toe-to-toe with the big fintech wolves—something these smaller guys desperately needed. It's a meaty move, no...

Continue Reading
PawnMate Boosts Inventory Efficiency for Pawnshops

Updated Category News Views 166

RFID Technology: Breathing New Life into Pawnshops Let's get things rolling with the cold, hard truth that pawnshops aren't exactly what most folks expect when it comes to cutting-edge technology. But times are a-changin', and PawnMate’s RFID Inventory Module is the latest twist in this industry storyline. It's like swapping out a rusty toolbox for a brand-new set of...

Continue Reading
Armada Moves up as Key Player in US SI Exports

Updated Category News Views 192

Pioneering New Grounds in Intelligence Infrastructure Hell of a move by Armada, stepping into the limelight as a priority team leader in the U.S. SI Exports Program. The whole gig is under the Department of Commerce's belt, pushing the frontier of America's Super Intelligence (SI) technology to buddies across the globe. It's like watching the next big blockbuster unfold...

Continue Reading

Top 5 Most Recently Viewed Articles

Understanding Blockchain: The Basics You Need to Know

Updated Category Crypto Views 1223

Blockchain technology has emerged as a transformative force in the digital age. While it is widely recognized for powering cryptocurrencies like Bitcoin and Ethereum, its applications extend to healthcare, supply chain management, and even secure voting systems. To unlock its full potential, it’s important to understand how blockchain functions, its defining...

Continue Reading
Navigating SAP S/4HANA Migration: CFOs and CIOs Strategies

Updated Category News Views 277

Critical SAP S/4HANA Migration Strategies for CFOs and CIOs As companies face a significant transformation wave valued at approximately $100 billion, the impending SAP S/4HANA migration deadline is giving rise to tensions between CFOs and CIOs. Data indicates that over 22,000 businesses worldwide must adapt to this migration, leaving little time and presenting numerous...

Continue Reading
New Perspective Expands Opportunities for Senior Living

Updated Category News Views 74

New Perspective Unveils its Latest Senior Living Community New Perspective, a dynamic senior living organization headquartered in Minnesota, has officially opened its first location in Missouri, bringing a fresh approach to senior care in the greater St. Louis area. This new community, located in Weldon Spring, is designed to offer a comfortable and engaging living...

Continue Reading
Exploring the Future of Server Operating Systems Growth

Updated Category News Views 376

Overview of the Server Operating System Market The global server operating system market is on the brink of significant expansion, having been valued at US$ 21.15 billion in 2024 and projected to soar to US$ 43.35 billion by the year 2033. This dramatic growth, expected at a compound annual growth rate (CAGR) of 8.3% between 2025 and 2033, is a testament to the ongoing...

Continue Reading
Workwhile Introduces RISE to Transform Wage Growth Insights

Updated Category News Views 244

Workwhile Unveils the Revolutionary RISE Indicator RISE provides instant insight into how wages are keeping pace with inflation During a recent conference, Workwhile, an AI-powered labor platform dedicated to improving worker experiences, introduced its latest development, the RISE (Rate of Increase of Salary and Earnings) Indicator. This innovative tool builds upon the...

Continue Reading